CHATTANOOGA, TENNESSEE, USA, September 14, 2022 – BioRegenx, Inc. and its subsidiary, NuLife Sciences, Inc announces a new peer-reviewed study on microvascular dysfunction in sepsis that included the use of GlycoCheck™, an FDA registered Class 1 medical testing device.
The study, titled Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study was published in Critical Care. Critical Care is a peer-reviewed, international clinical medical journal that provides a comprehensive overview of the intensive care field. One of the co-authors of the study is Dr. Hans Vink, Chief Science Officer of BioRegenx.
For the first time, we can now determine quantitative microvascular scores that correlate very well with accepted clinical parameters in individual sepsis patients for a wide range of clinical severities,” said Dr. Vink, who is also the inventor of GlycoCheck™.
“The new GlycoCheck™ software system represents a significant upgrade for researchers and healthcare practitioners,” said Robert Long, Chairman of BioRegenx. “For several years, GlycoCheck™ has been used globally in groundbreaking research to understand the complex nature of the endothelial glycocalyx.”
“The NOSTRADAMUS study confirms what we’ve suspected for some time,” Long adds, “that GlycoCheck™ should be in every emergency room and hospital to quickly evaluate patients to identify the severity of septic shock.”
The study concludes that new important diameter-specific quantification and differentiated analysis of RBC kinetics is a key to understanding microvascular dysfunction in sepsis. The flow corrected MicroVascular Health Score™ (MVHSdynamic), which has a broad bandwidth to detect micro-vascular (dys-) function, might serve as a valuable tool to detect microvascular impairment in critically ill patients.
About GlycoCheck
GlycoCheck™, an FDA registered Class 1 medical testing device developed by GlycoCheck B.V., analyzes glycocalyx, endothelium, and capillary function. It analyzes capillaries that are as small as 4 microns, so small that 100 of these tiny capillaries fit inside a human hair. GlycoCheck™ testing has been used as part of 91 peer-reviewed research studies from hospitals and universities worldwide. GlycoCheck is patented in the U.S., Canada, Europe, China, and Japan and is distributed by NuLife Sciences.
About NuLife Sciences
NuLife Sciences, Inc., (NuLifeSciences.com) is a research development, marketing and distribution company whose mission is to harness advanced technologies to redefine health and longevity from the inside out. We achieve this by increasing understanding of the biology that controls lifespan and anti-aging in the human body. We represent best in class products that enable people to lead longer and healthier lives. NuLife Sciences is wholly owned subsidiary of parent company, BioRegenx (BioRegenx.com), a holding company.
About BioRegenx
BioRegenx, Inc., (BioRegenx.com) a holding company, is the parent company of three wholly owned subsidiaries, Microvascular Health Solutions, Inc., My Body Rx, Inc., and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property of the breakthrough GlycoCheck™ medical testing device, the patented nutraceutical Endocalyx Pro™, additional synergistic dietary supplement products sold under the My Body Rx brand, and a customer base of medical professionals and brand partners throughout North America.
Safe Harbor
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of BioRegenx, Inc., or its subsidiaries, to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and BioRegenx, Inc., or its subsidiaries, assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international
trade.
Robert Doran
NuLife Sciences
+1 800-398-9842
email us here
Visit us on social media:
Facebook
LinkedIn
